Biosensors Use Non-Invasive Urinalysis and AI for Quick Assessment of Cancer Treatment
By LabMedica International staff writers Posted on 18 Mar 2022 |
Immune checkpoint blockade (ICB) inhibitors have transformed the treatment of cancer and have become the frontline therapy for a broad range of malignancies because they work better than the previous standard of care. However, less than 25% of patients benefit from these drugs and it can also be difficult to tell in a timely fashion, if the treatment is working at all. A newly-developed system of synthetic biosensors will now enable a patient and doctor to quickly learn if an ICB therapy is working through the use of non-invasive urinalysis and artificial intelligence (AI).
The ICB drug activates protective T cells, which attack the tumor en masse. The T cells kill it with a deadly secretion of proteases called granzymes, part of the same class of enzymes found in the stomach that are used to digest food. For their study, researchers at the Georgia Institute of Technology (Atlanta, GA, USA) developed sensors to detect both T cell and tumor proteases (tumors also secrete a type of protease) during ICB treatment. The sensors are attached to the ICB drug that makes its way toward the tumor environment after injection. When they reach their destination, the sensors are activated by proteases produced by both T cells and tumor cells, which triggers the release of signaling fluorescent reporters that are designed to concentrate into urine. A second way of reading the biosensor reporters involves AI and machine learning techniques to identify signal patterns that discriminate between the different ways the drug can fail. The biosensors can tell if the drug is working and can discriminate between two mechanisms of intrinsic resistance - both due to mutations in different protein coding genes.
“We reasoned, if patients are responding to the drug, it means these T cells are making proteases, and if they’re not responding, these proteases are not present, so the T cells are not active,” said Gabe Kwong, associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. “Basically, these signals would be diluted in blood and would be very hard to pick up, but everything from your blood gets filtered through the kidneys. So when we look at the urine, we get very concentrated signals, which increase or decrease, corresponding to whether the patients are responding or not.”
Related Links:
Georgia Institute of Technology
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines